These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 8123946)

  • 1. Assessment of cost-effective antibiotic therapy in the management of infections in cancer patients.
    Cimino MA; Rotstein CM; Moser JE
    Ann Pharmacother; 1994 Jan; 28(1):105-11. PubMed ID: 8123946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of pharmacist interventions on rational prophylactic antibiotic use and cost saving in elective cesarean section.
    Wang J; Dong M; Lu Y; Zhao X; Li X; Wen A
    Int J Clin Pharmacol Ther; 2015 Aug; 53(8):605-15. PubMed ID: 26104036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibiotic management and early discharge from hospital: an economic analysis.
    Gray A; Dryden M; Charos A
    J Antimicrob Chemother; 2012 Sep; 67(9):2297-302. PubMed ID: 22623630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effective approaches to antimicrobial use in oncology patients.
    Goff DA
    Curr Opin Infect Dis; 2002 Dec; 15(6):565-8. PubMed ID: 12821831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibiotic use and cost indicators at a rural hospital: a pilot project.
    Mylotte JM; Weislo P
    Am J Infect Control; 2000 Dec; 28(6):415-20. PubMed ID: 11114611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness evaluation of ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections accounting for antibiotic resistance.
    Jansen JP; Kumar R; Carmeli Y
    Value Health; 2009; 12(2):234-44. PubMed ID: 20667059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy, tolerability, and cost savings associated with the use of open-label metronidazole plus ceftriaxone once daily compared with ticarcillin/clavulanate every 6 hours as empiric treatment for diabetic lower-extremity infections in older males.
    Clay PG; Graham MR; Lindsey CC; Lamp KC; Freeman C; Glaros A
    Am J Geriatr Pharmacother; 2004 Sep; 2(3):181-9. PubMed ID: 15561650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients.
    Vázquez L; Encinas MP; Morín LS; Vilches P; Gutiérrez N; García-Sanz R; Caballero D; Hurlé AD
    Haematologica; 1999 Mar; 84(3):231-6. PubMed ID: 10189388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is procalcitonin-guided antimicrobial use cost-effective in adult patients with suspected bacterial infection and sepsis?
    Harrison M; Collins CD
    Infect Control Hosp Epidemiol; 2015 Mar; 36(3):265-72. PubMed ID: 25695167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic impact of standard antibiotic therapy combined with amikacin, in clinical unit, Lodz, Poland--part II.
    Kusowska J
    Acta Pol Pharm; 2005; 62(6):491-5. PubMed ID: 16583990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic impact of standard antibiotic therapy combined with amikacin, in clinical unit, Lodz, poland--part I.
    Kusowska J
    Acta Pol Pharm; 2005; 62(6):485-90. PubMed ID: 16583989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness comparison of sequential ofloxacin versus standard switch therapy.
    Partsch DJ; Paladino JA
    Ann Pharmacother; 1997 Oct; 31(10):1137-45. PubMed ID: 9337437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy and cost-effectiveness of outpatient parenteral antibiotic therapy (OPAT): a UK perspective.
    Chapman AL; Dixon S; Andrews D; Lillie PJ; Bazaz R; Patchett JD
    J Antimicrob Chemother; 2009 Dec; 64(6):1316-24. PubMed ID: 19767623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of pharmacist interventions on antibiotic use in the general pediatric ward.
    Tian J; Wang MM; Jiang X; Liu L; Tian Z
    Pak J Pharm Sci; 2020 May; 33(3(Special)):1389-1395. PubMed ID: 33361028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The other side of the coin: socioeconomic analysis of antibiotic resistance].
    García-Altés A; Jovell AJ; Aymerich M
    Enferm Infecc Microbiol Clin; 1999; 17 Suppl 2():27-31. PubMed ID: 10605187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective trial of a clinical pharmacy intervention in a primary care practice in a capitated payment system.
    Altavela JL; Jones MK; Ritter M
    J Manag Care Pharm; 2008; 14(9):831-43. PubMed ID: 19006440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibiotic combinations with redundant antimicrobial spectra: clinical epidemiology and pilot intervention of computer-assisted surveillance.
    Glowacki RC; Schwartz DN; Itokazu GS; Wisniewski MF; Kieszkowski P; Weinstein RA
    Clin Infect Dis; 2003 Jul; 37(1):59-64. PubMed ID: 12830409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic impact simulation analysis of use of tigecycline, as appropriate, in first-course antibiotic therapy for complicated intra-abdominal infections in intensive care patients.
    Ancona F
    Minerva Med; 2010 Oct; 101(5):319-28. PubMed ID: 21048554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Markov model of the cost-effectiveness of pharmacist care for diabetes in prevention of cardiovascular diseases: evidence from Kaiser Permanente Northern California.
    Yu J; Shah BM; Ip EJ; Chan J
    J Manag Care Pharm; 2013 Mar; 19(2):102-14. PubMed ID: 23461426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of a multidisciplinary team review of potential outpatient parenteral antimicrobial therapy prior to discharge from an academic medical center.
    Heintz BH; Halilovic J; Christensen CL
    Ann Pharmacother; 2011 Nov; 45(11):1329-37. PubMed ID: 21990938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.